Filtered By:
Infectious Disease: HIV AIDS
Vaccination: Cancer Vaccines

This page shows you your search results in order of date.

Order by Relevance | Date

Total 21 results found since Jan 2013.

M024 don ’t stop hpv vaccine with one dose left, go see an allergist!
HPV is the most common sexually transmitted infection in the US. HPV is associated with cervical, vulvar, and vaginal cancer in females, penile cancer in males, and anal and oropharyngeal cancer in both females and males. FDA-approved in 2014, human papillomavirus vaccine (9vHPV, Merck), aids in the prevention of diseases caused by nine types of HPV. 9vHPV is now licensed in the US for females and males ages 9 through 45 years. For those 15 years and older, a 3-dose schedule is recommended.
Source: Annals of Allergy, Asthma and Immunology - November 1, 2021 Category: Allergy & Immunology Authors: M. Lukas, M. Tankersley Source Type: research

What We Learned About Genetic Sequencing During COVID-19 Could Revolutionize Public Health
You don’t want to be a virus in Dr. David Ho’s lab. Pretty much every day since the COVID-19 pandemic began, Ho and his team have done nothing but find ways to stress SARS-CoV-2, the virus that causes the disease. His goal: pressure the virus relentlessly enough that it mutates to survive, so drug developers can understand how the virus might respond to new treatments. As a virologist with decades of experience learning about another obstinate virus, HIV, Ho knows just how to apply that mutation-generating stress, whether by starving the virus, bathing it in antibodies that disrupt its ability to infect cells, ...
Source: TIME: Health - June 11, 2021 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 feature Genetics Magazine Source Type: news

Anthony Fauci, 100 Days Into the Biden Administration, Is Finally Getting to Do His Job
When Dr. Anthony Fauci arrived at 1600 Pennsylvania Ave. for his first White House press briefing under the new Biden Administration, he could see things would be different. It was the day after the Inauguration, and President Joe Biden was eager to get the country’s COVID-19 response back on track. Five minutes before he addressed the public, Fauci spoke with the new President. “He said, ‘I want you to just go and tell the science, explain to people that if we make mistakes, we’re going to fix the mistakes and we’re not going to dwell on the mistakes. Let science be communicated to the public...
Source: TIME: Health - May 18, 2021 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 Source Type: news

NIDCR's Spring 2021 E-Newsletter
Having trouble viewing this email? View it as a Web page. NIDCR's Spring 2021 E-Newsletter In this issue: NIDCR News Funding Opportunities & Related Notices NIH/HHS News Subscribe to NICDR News Science Advances   Grantee News   NIDCR News NIDCR & NIH Stand Against Structural Racism NIDCR Director Rena D’Souza, DDS, MS, PhD, said in a statement that there is no place for structural racism in biomedical research, echoing remarks from NIH Director Francis Collins, MD, PhD, in his announcement of a new NIH initiative—called UNIT...
Source: NIDCR Science News - April 7, 2021 Category: Dentistry Source Type: news

Epstein-Barr Virus Antibody That Blocks Fusion And Neutralizes Virus Infection of B Cells
Epstein-Barr virus (EBV) is the most common cause of infectious mononucleosis and is associated with nearly 200,000 cancers and 140,000 deaths each year. EBV-associated cancers include Hodgkin ' s lymphoma, non-Hodgkin ' s lymphoma, Burkitt B cell lymphoma, and EBV post-transplant lymphoproliferative disease. The latent reservoir for EBV in the body is the B lymphocyte. Thus, blocking B cell infection is important for reducing EBV-related disease.EBV can infect both B cells and epithelial cells; however, the method of entry differs between these two cell types. To initiate B cell infection, EBV glycoprotein 350 (gp350) bin...
Source: NIH OTT Licensing Opportunities - February 16, 2021 Category: Research Authors: ott-admin Source Type: research

mRNA Technology Gave Us the First COVID-19 Vaccines. It Could Also Upend the Drug Industry
“No!” The doctor snapped. “Look at me!” I had been staring her in the eyes, as she had ordered, but when a doctor on my other side began jabbing me with a needle, I started to turn my head. “Don’t look at it,” the first doctor said. I obeyed. This was in early August in New Orleans, where I had signed up to be a participant in the clinical trial for the Pfizer-BioNTech COVID-19 vaccine. It was a blind study, which meant I was not supposed to know whether I had gotten the placebo or the real vaccine. I asked the doctor if I would really been able to tell by looking at the syringe. &...
Source: TIME: Health - January 11, 2021 Category: Consumer Health News Authors: Walter Isaacson Tags: Uncategorized COVID-19 feature Magazine Source Type: news

Top Global Health Moments of 2020
By The Editorial Team, IntraHealth International Community Health Nurse Olivia Yeboah thoroughly washes her hands at the Akropong Clinic in Ghana. Photo by Emmanuel Attramah, PMI Impact Malaria/US President ' s Malaria Initiative.December 17, 2020If we wanted to, we could list a COVID-19 moment for every month of 2020.  We all know that the onset of the coronavirus pandemic—first in China and then worldwide—overwhelmed news coverage this year. And with good reason. It’s the first large-scale global pandemic in 100 years. At the time this article was pu...
Source: IntraHealth International - December 17, 2020 Category: International Medicine & Public Health Authors: kseaton Tags: HIV & AIDS COVID-19 Nutrition Policy Advocacy Health Workforce Systems Nursing Midwifery 2020 Health Workers Source Type: news

NIDCR's Winter 2020 E-Newsletter
Having trouble viewing this email? View it as a Web page. NIDCR's Winter 2020 E-Newsletter In this issue: NIDCR News Funding Opportunities NIH/HHS News Funding Notices Science Advances Subscribe to NICDR News Grantee News   NIDCR News NIDCR Welcomes New Director Rena D’Souza Rena N. D’Souza, DDS, MS, PhD, was sworn in as the director of NIDCR by NIH Director Francis S. Collins, MD, PhD, on October 13. Prior to joining NIH, Dr. D’Souza was the assistant vice president for academic affairs and education for health sciences at the Unive...
Source: NIDCR Science News - December 4, 2020 Category: Dentistry Source Type: news

UCLA draws record $1.4 billion in research funding
UCLA attracted record support for its wide-ranging research in the 2019 –20 fiscal year, receiving $1.427 billion in research funding.2020 is the third consecutive year that the university has topped its previous best. Research support has grown by 38% since 2015. UCLA now ranks sixth among all universities in total research expenditures.“This is a tribute to the great work being done across disciplines at UCLA,” said Roger Wakimoto, vice chancellor for research. “These funds help bring about major breakthroughs in medical science, advance knowledge in numerous other disciplines, strengthen our teaching, and suppor...
Source: UCLA Newsroom: Health Sciences - October 12, 2020 Category: Universities & Medical Training Source Type: news

Use of Ultraviolet Blood Irradiation Against Viral Infections
AbstractUltraviolet blood irradiation (UBI) was used with success in the 1930s and 1940s for a variety of diseases. Despite the success, the lack of understanding of the detailed mechanisms of actions, and the achievements of antibiotics, phased off the use of UBI from the 1950s. The emergence of novel viral infections, from HIV/AIDS to Ebola, from SARS and MERS, and SARS-CoV-2, bring back the attention to this therapeutical opportunity. UBI has a complex virucidal activity, mostly acting on the immune system response. It has effects on lymphocytes (T-cells and B-cells), macrophages, monocytes, dendritic cells, low-density...
Source: Clinical Reviews in Allergy and Immunology - October 6, 2020 Category: Allergy & Immunology Source Type: research

Vaccines, Antibodies and Drug Libraries. The Possible COVID-19 Treatments Researchers Are Excited About
In early April, about four months after a new, highly infectious coronavirus was first identified in China, an international group of scientists reported encouraging results from a study of an experimental drug for treating the viral disease known as COVID-19. It was a small study, reported in the New England Journal of Medicine, but showed that remdesivir, an unapproved drug that was originally developed to fight Ebola, helped 68% of patients with severe breathing problems due to COVID-19 to improve; 60% of those who relied on a ventilator to breathe and took the drug were able to wean themselves off the machines after 18...
Source: TIME: Health - April 14, 2020 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 Source Type: news

NIH Slated for 7 percent Budget Cut
The President has proposed a $38.7 billion budget for the National Institutes of Health in fiscal year (FY) 2021. This translates to a $3 billion or 7 percent cut in the agency’s funding compared to FY 2020. The NIH budget request includes a $50 million initiative to use artificial intelligence (AI) to develop a better understanding of the causes of chronic diseases and to identify early treatments. This plan is in line with the Administration’s “Industries of the Future” effort, which supports using and developing AI across sectors. The budget would provide $50 million for the Childhood Cancer ...
Source: Public Policy Reports - February 18, 2020 Category: Biology Authors: AIBS Source Type: news

Leukocyte Heparanase: A Double-Edged Sword in Tumor Progression
Conclusions This review describes how leukocyte-heparanase can be a double-edged sword in tumor progression; it can enhance tumor immune surveillance and tumor cell clearance, but also promote tumor survival and growth. We also discuss the potential of using heparanase in leukocyte therapies against tumors, and the effects of heparanase inhibitors on tumor progression and immunity. We are just beginning to understand the influence of heparanase on a pro/anti-tumor immune response, and there are still many questions to answer. How do the pro/anti-tumorigenic effects of heparanase differ across different cancer types? Does...
Source: Frontiers in Oncology - April 29, 2019 Category: Cancer & Oncology Source Type: research

Mind the Gap: How Interspecies Variability in IgG and Its Receptors May Complicate Comparisons of Human and Non-human Primate Effector Function
Conclusions The sheer number of factors to consider when translating observations between macaques and humans makes the process a challenging, multidimensional one. Differences in the structures and activities of IgG subclasses, and polymorphisms in protein sequence and post-translational modification of antibody receptors are a subset of the many relevant considerations. Copy number variation, splice variants, and alleles with sequence variation outside of coding regions have been associated with a diversity of phenotypes in humans (183, 213–217), and are presumed to exist in NHP. A number of differences in the p...
Source: Frontiers in Immunology - April 7, 2019 Category: Allergy & Immunology Source Type: research